You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

envafolimab

Showing 1 - 25 of 52
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Nasopharyngeal Carcinoma Trial in Hangzhou (Endostar and Envafolimab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Endostar and Envafolimab
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Sep 24, 2023

Advanced Mucosal Melanoma Trial (Envafolimab combined with recombinant human endostatin and first-line chemo)

Not yet recruiting
  • Advanced Mucosal Melanoma
  • Envafolimab combined with recombinant human endostatin and first-line chemotherapy
  • (no location specified)
Sep 15, 2023

Gallbladder Cancer Trial (Envafolimab+Gemox)

Not yet recruiting
  • Gallbladder Cancer
  • (no location specified)
Aug 25, 2023

Lung Tumors Trial (Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy), Envafolimab combined

Not yet recruiting
  • Lung Neoplasms
  • Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy)
  • Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy)
  • (no location specified)
Jun 12, 2023

Healthy Male Trial in Beijing (Envafolimab with new manufacturing process, Envafolimab with old manufacturing process)

Not yet recruiting
  • Healthy Male
  • Envafolimab with new manufacturing process
  • Envafolimab with old manufacturing process
  • Beijing, Beijing, China
    Beijing Gaobo Boren Hosipital
May 9, 2023

Advanced NSCLC Trial (Trilaciclib+Envafolimab+Docetaxel, Envafolimab+Docetaxel, Docetaxel)

Not yet recruiting
  • Advanced Non-Small Cell Lung Cancer
  • (no location specified)
Jun 16, 2023

Immunotherapy;Envafolimab; Esophageal Cancer Trial (Envafolimab, Abraxane, Cisplatin)

Not yet recruiting
  • Immunotherapy;Envafolimab; Esophageal Cancer
  • Envafolimab
  • +2 more
  • (no location specified)
Apr 24, 2023

NSCLC Trial in Suzhou (Envafolimab Injection)

Recruiting
  • NSCLC
  • Envafolimab Injection
  • Suzhou, Jiangsu, China
    Northern Jiangsu People's Hospital
Oct 29, 2023

Nasopharyngeal Carcinoma Trial (Envafolimab and recombinant human endostatin combined with chemoradiotherapy)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Envafolimab and recombinant human endostatin combined with chemoradiotherapy
  • (no location specified)
Sep 23, 2023

Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma

Not yet recruiting
  • Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients
  • Surufatinib + envafolimab
  • (no location specified)
Feb 1, 2023

Metastatic Colorectal Cancer Trial (Cetuximab + Envafolimab + mFOLFOXIRI, Cetuximab + mFOLFOX6/FOLFIRI)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • Cetuximab + Envafolimab + mFOLFOXIRI
  • Cetuximab + mFOLFOX6/FOLFIRI
  • (no location specified)
Jul 24, 2023

Envafolimab Combined With Endostar and Concurrent

Not yet recruiting
  • Cervical Cancer
  • (no location specified)
May 19, 2023

A Prospective, Randomized Controlled Study of Cyclophosphamide,

Not yet recruiting
  • Epithelial Ovarian Cancer
  • Envafolimab
  • Shijiazhuang, Hebei, China
    Hebei
Aug 20, 2023

Metastatic Colorectal Cancer Trial in Nanjing (Envafolimab, Trifluridine/Tipiracil, Bevacizumab)

Recruiting
  • Metastatic Colorectal Cancer
  • Envafolimab
  • +2 more
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital with Nanjing Medical University
Sep 24, 2023

Locally Advanced Cervical Cancer Trial in Chongqing (Envafolimab, Cisplatin, External Beam Radiotherapy (EBRT))

Not yet recruiting
  • Locally Advanced Cervical Cancer
  • Envafolimab
  • +3 more
  • Chongqing, CHN, China
    Chongqing university Cancer Hospital
Apr 3, 2023

Neoadjuvant Envafolimab in Resectable and Locally Advanced

Not yet recruiting
  • Locally Advanced Rectal Carcinoma
  • MSI-High
  • Envafolimab
  • (no location specified)
Dec 9, 2022

Gastric / Gastroesophageal Junction Adenocarcinoma Trial in Shanghai (envafolimab and lenvatinib combined with

Enrolling by invitation
  • Gastric / Gastroesophageal Junction Adenocarcinoma
  • envafolimab and lenvatinib combined with paclitaxel-albumin
  • Shanghai, Shanghai, China
    Fudan University Cancer Hospital
Sep 3, 2023

Advanced Sarcoma, Metastatic Sarcoma, Soft Tissue Sarcoma Trial (YH001, Envafolimab, Doxorubicin)

Recruiting
  • Advanced Sarcoma
  • +2 more
  • Santa Monica, California
    Sarcoma Oncology Center
Dec 5, 2022

Rectal Cancer Trial in Hangzhou (Envafolimab)

Recruiting
  • Rectal Cancer
  • Envafolimab
  • Hangzhou, Zhejiang, China
    Sir Run Run Shaw Hospital, Zhejiang University School of Medicin
May 4, 2023

Rectal Cancer Trial in Hangzhou (Envafolimab)

Not yet recruiting
  • Rectal Cancer
  • Envafolimab
  • Hangzhou, Zhejiang, China
    Sir Run Run Shaw Hospital, Zhejiang University School of Medicin
Mar 1, 2023

Locally Advanced Nasopharyngeal Carcinoma, Envafolimab, Induction Chemo Trial in Guangzhou (Envafolimab Plus Chemoradiotherapy)

Recruiting
  • Locally Advanced Nasopharyngeal Carcinoma
  • +3 more
  • Envafolimab Plus Chemoradiotherapy
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 9, 2022

Colorectal Tumors Trial (Envafolimab, recombinant human endostatin (endostatin))

Not yet recruiting
  • Colorectal Neoplasms
  • Envafolimab
  • recombinant human endostatin (endostatin)
  • (no location specified)
Sep 19, 2022

Esophageal Squamous Cell Carcinoma Trial (Envafolimab, Albumin-Bound Paclitaxel, Carboplatin)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Envafolimab
  • +2 more
  • (no location specified)
Sep 21, 2022

Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma Trial (fruquintinib, Envafolimab)

Not yet recruiting
  • Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
  • (no location specified)
Jul 10, 2023

Objective Response Rate (ORR) Trial (Envafolimab, Lenvatinib Combined With TACE)

Not yet recruiting
  • Objective Response Rate (ORR)
  • Envafolimab, Lenvatinib Combined With TACE
  • (no location specified)
Oct 13, 2022